ArticleFrontiers in medical technology2025
Infrared imaging and intravascular laser irradiation of blood therapy for glycemic control in type 2 diabetes mellitus: a technical note.
Article in Frontiers in medical technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This technical note presents a standardized method that integrates intravascular laser irradiation of blood (ILIB) with infrared thermography to visualize real-time physiological responses during treatment. One adult male with long-standing type 2 diabetes underwent ten ILIB sessions using a 660 nm transcutaneous laser applied over the left radial artery. Infrared thermography captured temperature changes in abdominal regions associated with metabolic function. Across sessions, an average temperature increase of approximately 2.1 °C was observed in the hepatic and epigastric areas. Laboratory values showed reductions in fasting glucose (-29%) and HbA1c (-14%), while C-peptide remained stable. Because this is a single-patient technical demonstration, the findings cannot be interpreted as evidence of efficacy. Instead, the report illustrates the feasibility and potential utility of combining ILIB with thermal imaging for methodological development in future controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.